GHGuardant Health, Inc.

Nasdaq guardanthealth.com


$ 25.37 $ -0.88 (-3.35 %)    

Friday, 17-May-2024 15:59:56 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 25.36
$ 25.53
$ 25.35 x 200
$ 0.00 x 0
$ 25.08 - $ 26.12
$ 15.81 - $ 41.06
2,589,751
na
3.09B
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-22-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-19-2019 12-31-2018 10-K
23 11-19-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guardant-healths-real-world-data-supporting-performance-of-shield-blood-test-for-crc-presented-at-2024-digestive-disease-week

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will present data from two real-wor...

 correction-guardant-health-q1-2024-adj-eps-046-beats-085-estimate-sales-168500m-beat-150673m-estimate

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.85)...

 canaccord-genuity-maintains-buy-on-guardant-health-lowers-price-target-to-30

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 ...

 craig-hallum-assumes-guardant-health-at-buy-announces-price-target-of-28

Craig-Hallum analyst Alex Nowark assumes Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $28.

 goldman-sachs-maintains-buy-on-guardant-health-lowers-price-target-to-28

Goldman Sachs analyst Matthew Sykes maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $32 to...

 guggenheim-reiterates-neutral-on-guardant-health

Guggenheim analyst Subbu Nambi reiterates Guardant Health (NASDAQ:GH) with a Neutral.

 rex-american-resources-reports-upbeat-earnings-joins-avalo-therapeutics-rh-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...

 insiders-buying-advance-auto-parts-and-2-other-stocks

Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades.

 cancer-test-focused-guardant-health-stock-falls-on-fda-adcom-update-for-colorectal-test

Guardant Health surpasses Q4 2023 revenue expectations, reporting $155.1 million. Precision oncology revenue is up 25% to $142....

 canaccord-genuity-maintains-buy-on-guardant-health-lowers-price-target-to-45

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $50 ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION